Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.35 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | TEK | Q02763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152650 | 0.87 | ABL1 (0.43) | GRM5ADORA2ARETABL1PIK3CA | |
| SCHEMBL5149232 | 0.86 | RET (0.35) | ADORA2ARETABL1PIK3CAPIK3CG | |
| SCHEMBL5147922 | 0.83 | USP8 (0.46) | ADORA2ARETABL1PIK3CAPIK3CG | |
| SCHEMBL5147962 | 0.83 | USP8 (0.46) | ADORA2ARETABL1PIK3CAPIK3CG | |
| SCHEMBL5149167 | 0.83 | ADORA2A (0.35) | ADORA2ARETABL1PIK3CAPIK3CG | |
| SCHEMBL5149170 | 0.80 | PIK3CD (0.34) | ADORA2ARETABL1PIK3CAPIK3CG | |
| SCHEMBL5147958 | 0.80 | ADORA2A (0.39) | ADORA2ARETABL1PIK3CAPIK3CG | |
| SCHEMBL5149021 | 0.80 | CYP1A2 (0.32) | GRM5RETABL1 | |
| SCHEMBL5148960 | 0.79 | POLB (0.39) | ADORA2ARETABL1PIK3CAPIK3CG | |
| SCHEMBL5147937 | 0.79 | TP53 (0.37) | ADORA2ARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | GRM5 144/4885ADORA2A 1/4885ADK 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.